Market closed·Syncing…
Market closed · Close · 19 Nov

Krishna Institute of Medical Sciences Limited KIMSshare price and chart

Krishna Institute of Medical Sciences closed at ₹767.80 on 19 November 2026, up 1.16% on the day. The 52-week range is ₹575.80 to ₹858.00.

₹767.80The price one share last traded at, in rupees.+1.16% · ₹8.80
52-wk low ₹57668% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹858

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on KIMS

Real prices, every charge counted. Pick one or write your own.
What Krishna Institute of Medical Sciences Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Krishna Institute of Medical Sciences runs hospitals, 96.8% of its turnover, offering services across 40 specialties including cardiac sciences, oncology, neurosciences, orthopaedics, organ transplantation, renal sciences and mother and child care, for insured and uninsured patients in three states.

1
1Sector

Healthcare Services

2
2What it sells

Multi-specialty hospital care

3
3Who buys it

Insured and uninsured patients

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
64.6Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
50%Near average
today 50%20d avg 57.3%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+4.7%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+4.6%1 monthHow much the share price has changed over the period.+13.9%3 monthsHow much the share price has changed over the period.▼ 2.6%1 yearHow much the share price has changed over the period.+13.2%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.25.7%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹32,248 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.147.1xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.9.7%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.8.20xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.9.9%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.43.3xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.83xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-23.5%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Hospital · 28 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.147.09vs 54.16 median
Cheapest: INDRAMEDCO 17.2Priciest: HCG 866.06
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.4.29%vs 10.24% median
Lowest: MAITREYA -7.51%Highest: KMCSHIL 17.52%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.39.94%vs 21.54% median
Lowest: SANGANI -44.94%Highest: GKSL 194.62%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 4 Nov 2026), sales rose 39.9% from a year earlier to ₹1,344 cr and profit rose 3.6% to ₹74.6 cr.

Going well
  • Sales grew 3 years running (₹2,198 cr in FY23 to ₹3,905 cr in FY26).
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
Worth watching
  • Operating margin fell from 27.5% in FY23 to 20.5% in FY26.
  • Debt to equity rose 3 years running (0.35 to 1.27).
  • Promoters had pledged 11.7% of their shares at the end of September 2026, 3.83% of all shares.
  • Promoter holding fell 6.2 points over 7 quarters (38.82% to 32.66%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 18 results, the share rose on 11 and fell on 7, and moved by 3% or more on 3.

+9%
-9%
Q4 FY22Q4 FY23Q4 FY24Q4 FY25Q2 FY27

Q2 FY27: results filed 4 Nov 2026. The share went from its close on 3 Nov 2026 to its close on 5 Nov 2026 +0.08%.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+25.0%a year, over 5 years
1 yr
+15.7%
3 yr
+27.3%
5 yr
+25.0%

Held for 5 years this compounded at +25.0% a year. The last twelve months were up +15.7%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
32.66%promoter holding, as of 2026-09-30-6.2 pts since 2021
Promoter share since listing
2021-0632.66% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
32.7%
15.0%
33.2%
19.1%
Promoter32.7%Foreign (FII)15.0%Domestic (DII)33.2%Public & others19.1%
Who is buying, who is leavingMar 25 to Sep 26
Promoter32.7%-6.2 pts
Foreign (FII)15.0%-0.4 pts
Domestic (DII)33.2%+1.3 pts

Each line is that holder's share of all shares over the last 8 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.11.71%of promoter shares, as at 2026-09-30

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Others14-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about O & M Agreement

Analysts/Institutional Investor Meet/Con. Call Updates11-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Transcript

Analysts/Institutional Investor Meet/Con. Call Updates10-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates10-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates05-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Link of Recording

Copy of Newspaper Publication05-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Copy of Newspaper Publication

Statement of deviation(s) or variation(s) under Reg. 3204-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

Statement of deviation(s) or variation(s) under Reg. 3204-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

Monitoring Agency Report04-Nov-2026

PREF REPORT

Monitoring Agency Report04-Nov-2026

Monitoring Agency Report-QIPO

Amalgamation/Merger04-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Amalgamation/Merger

Change in Director(s)04-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Change in Director(s) of the company.

Investor Presentation04-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor Presentation

Press Release04-Nov-2026

Krishna Institute of Medical Sciences Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release Q2FY27".

Outcome of Board Meeting04-Nov-2026

Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Backtest idea · KIMSMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on KIMS
Backtest idea · KIMSLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on KIMS
Backtest idea · KIMSSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on KIMS
Your own ideaWrite a rule for KIMS in plain English“Buy KIMS when …”
Start writing
Buy the dip on KIMSBuy when RSI(14) drops below 30
52-week high breakout on KIMSBuy when closes at a 52-week high
Golden cross on KIMSBuy when 50-day EMA crosses above 200-day
Stochastic oversold on KIMSBuy when stochastic %K drops below 20
Pullback in an uptrend on KIMSBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹32,248 cr
Larger than 75% of 28 peers
sector middle ₹4,337 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
147.1x
Higher than 91% of 22 peers
sector middle 54.2x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
8.2x
Higher than 85% of 26 peers
sector middle 5.5x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
9.7%
Lower than 72% of 18 peers
sector middle 12.3%
FY23 18.9%FY26 9.7%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
9.9%
Lower than 70% of 23 peers
sector middle 14.8%
FY23 19.7%FY26 9.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.83
Higher than 92% of 26 peers
sector middle 0.27
FY23 0.35FY26 1.27
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 46% of 28 peers
sector middle 0.0%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+39.9%
Higher than 77% of 22 peers
sector middle +21.5%
FY24 13.7%FY26 28.7%

Peers are the listed companies in the exchange's own industry group: Hospital. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.20.5%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+3.6%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹3,905 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹242 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹6.2 as profit. Other income added ₹0.7.

Where it wentPer ₹100 of sales
Running costs₹79.5Depreciation₹7.3Interest₹5.2Tax₹2.4Profit₹6.2
Profit per ₹100, year by year
FY23FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+21.1%-+39.9%
Profit▼ 12.9%-+3.6%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹1 Cr, after ₹1,428 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹511 Cr
Investing-₹1,452 Cr
Lenders and shareholders+₹940 Cr
Net change in cash-₹1 Cr
Operating cash per ₹100 of profit
₹118FY23₹155FY24₹140FY25₹211FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.·13.7%21.5%28.7%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.27.5%25.6%25.8%20.5%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.16.6%13.5%13.7%6.2%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.18.9%16.7%18.4%9.7%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.19.7%16.7%15.4%9.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.35x0.65x1.06x1.27x
Interest coverHow many times the company's profit before interest could pay its interest bill.16.9x10.8x7.2x2.6x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · KIMSStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on KIMS
Backtest idea · KIMSPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on KIMS
Backtest idea · KIMSBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on KIMS
Backtest idea · KIMS52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on KIMS
Backtest idea · KIMSGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on KIMS
MACD momentum on KIMSBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on KIMSBuy when closes below the lower Bollinger band
Supertrend rider on KIMSBuy when supertrend turns up
Buy the dip on KIMSBuy when RSI(14) drops below 30
52-week high breakout on KIMSBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Hospital
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
APOLLOHOSP
Apollo Hospitals Enterprise Limited
1.26 L cr56.0x11.8x21.5%20.7%0.508.4%+20.8%0.23%
MAXHEALTH
Max Healthcare Institute Limited
1.01 L cr73.3x8.9x14.3%14.4%0.3315.1%+20.3%0.19%
MANIPALHOS
Manipal Health Enterprises Limited
91,609 cr-5.5x--0.34--0.00%
ASTERDM
Aster DM Quality Care Limited
64,443 cr102.1x8.3x10.1%14.8%0.438.7%+136.3%0.41%
FORTIS
Fortis Healthcare Limited
61,140 cr58.9x5.8x11.0%13.5%0.2910.7%+17.3%0.12%
MEDANTA
Global Health Limited
39,747 cr64.2x9.2x15.0%17.9%0.1612.1%+33.6%0.03%
NH
Narayana Hrudayalaya Ltd.
38,279 cr44.3x7.7x19.7%16.0%0.998.4%+73.0%0.24%
KIMS
Krishna Institute of Medical Sciences Limited
32,248 cr147.1x8.2x9.7%9.9%0.834.3%+39.9%0.00%
AGARWALEYE
Dr. Agarwal's Health Care Limited
17,535 cr102.4x7.8x8.3%15.2%0.098.7%+31.4%0.00%
RAINBOW
Rainbow Childrens Medicare Limited
12,602 cr43.1x7.3x17.9%27.8%0.0015.5%+23.2%0.28%
YATHARTH
Yatharth Hospital & Trauma Care Services Limited
10,392 cr54.5x5.5x9.9%12.4%0.2412.2%+54.4%0.05%
PARKHOSPS
Park Medi World Limited
10,240 cr36.8x4.7x13.0%17.7%0.2014.7%-0.00%
JLHL
Jupiter Life Line Hospitals Limited
9,219 cr49.3x5.7x13.7%16.0%0.3611.4%+16.0%0.07%
HCG
Healthcare Global Enterprises Limited
9,181 cr866.1x6.8x1.9%9.4%0.520.8%+13.1%0.00%
ARTEMISMED
Artemis Medicare Services Limited
5,370 cr46.8x5.4x11.6%14.8%0.2410.0%+13.2%0.13%
INDRAMEDCO
Indraprastha Medical Corporation Limited
3,303 cr17.2x4.1x27.5%37.7%0.0012.3%+8.3%1.11%
KMCSHIL
K M C Speciality Hospitals (India) Limited
3,288 cr53.8x----17.5%+24.1%0.00%
DRAGARWQ
Dr Agarwals Eye Hospital Limited
2,819 cr37.0x----15.3%+22.3%0.07%
SHALBY
Shalby Limited
1,317 cr34.3x1.3x3.5%6.7%0.533.2%+9.7%0.00%
GKSL
Gujarat Kidney And Super Speciality Limited
1,187 cr55.1x4.5x6.6%8.6%0.0616.2%+194.6%0.00%
GPTHEALTH
GPT Healthcare Limited
1,087 cr20.9x3.8x16.3%23.1%0.0510.2%+14.1%0.76%
UNIHEALTH
Unihealth Hospitals Limited
774 cr-7.5x-16.2%0.13--0.00%
MOMSBELIEF
Rays of Belief Limited
573 cr-3.8x--0.15--0.00%
LOTUSEYE
Lotus Eye Hospital and Institute Limited
213 cr444.6x3.5x0.1%1.2%0.290.8%+35.9%0.00%
NEPHROCARE
Nephro Care India Limited
149 cr-2.4x-8.7%0.00--0.00%
MAITREYA
Maitreya Medicare Limited
78 cr-2.8x--2.2%0.85-7.5%-0.1%0.00%
SANGANI
Sangani Hospitals Limited
76 cr22.0x1.9x-19.6%0.008.7%-44.9%0.00%
AATMAJ
Aatmaj Healthcare Limited
58 cr102.8x1.1x-3.6%0.451.9%+56.9%0.00%
ABH
ABH Healthcare Limited
44 cr-0.9x--0.80--0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-0.8
+23.4
-16.6
+7.3
+13.8
+7.3
-1.2
-6.1
-1.2
-6.0
+9.4
·
+26.1%
11m
2025
+1.9
-14.5
+22.8
+2.7
+4.2
-1.6
+11.5
-3.6
-3.3
+3.0
-5.0
-11.2
+1.8%
2024
+7.9
+5.7
-8.8
-1.3
-10.2
+14.1
+3.0
+17.9
+9.9
-2.1
+8.2
+1.4
+51.1%
2023
-2.6
-10.8
+4.3
+7.8
+7.4
+10.2
+7.1
+4.4
-1.1
-4.5
+3.6
+1.2
+27.9%
2022
-5.5
-5.9
+9.1
-3.1
-2.1
-9.7
+4.8
-3.1
+25.8
-1.9
+0.8
+3.3
+8.5%
2021
·
·
·
·
·
·
+27.3
+6.6
-5.0
-8.7
+11.2
+14.9
+50.5%
6m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2025-09-05GOLDMAN SACHS BANK EUROPE SE - ODI · blockBUY2,45,154₹738.10₹18.09 Cr
2025-09-05GOLDMAN SACHS (SINGAPORE) PTE - ODI · blockSELL2,45,154₹738.10₹18.09 Cr
2025-09-02GOLDMAN SACHS BANK EUROPE SE - ODI · blockBUY5,01,458₹727.50₹36.48 Cr
2025-09-02GOLDMAN SACHS (SINGAPORE) PTE - ODI · blockSELL5,01,458₹727.50₹36.48 Cr
2025-08-29GOLDMAN SACHS BANK EUROPE SE - ODI · blockBUY2,51,598₹737.40₹18.55 Cr
2025-08-29GOLDMAN SACHS (SINGAPORE) PTE - ODI · blockSELL2,51,598₹737.40₹18.55 Cr
2024-08-28INFINITY PARTNERS · bulkBUY15,70,000₹2,497.00₹392.03 Cr
2024-08-28INFINITY PARTNERS · blockBUY15,70,000₹2,497.00₹392.03 Cr
Annual reports

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test KIMS. “Buy KIMS when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free